Hot Keywords
Biomarker Discovery Autophagy and Cancer Breast Cancer Metastasis Brain Metastases Gastric Cancer Metastasis Lung Cancer Genetic Heterogeneity Colorectal Cancer Prostate Cancer Cancer Immunotherapy Circulating Tumor Cells Neuroendocrine Tumors

Top
J Cancer Metastasis Treat 2022;8:[Accepted].10.20517/2394-4722.2022.05© The Author(s) 2022
Accepted Manuscript
Open AccessReview

Follicular lymphoma: the diminishing role of chemotherapy 

Correspondence Address: Prof. Pier Luigi Zinzani, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna 40138, Italy. E-mail: pierluigi.zinzani@unibo.it

...

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Abstract

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (iNHL), accounting for 70% of them in Western countries. Despite this unique name, FL is an extremely heterogeneous disease, both clinically and biologically. The basis of FL heterogeneity lies in the different biological pathways which can be activated, because of the variety of gene mutations that can occur. Today, there is a growing interest in the knowledge of these activated pathways, which is also testified by the presence of a new model that incorporates FL mutations to define patient’s prognosis (m7-FLIPI). These evaluations are appealing also because of the recent possibility to use “targeted therapies”. Targeted therapies are new tools, currently applicable in the setting of relapse/refractory (R/R) disease, where we can find a great variety of “chemo-free” combinations. As in other hematologic malignancies, “cellular therapy” enriches FL drug scenario, including T cell dependent bispecific antibodies and chimeric antigen receptor T (CAR-T) cells. Since FL heterogeneity is the basis of the difference in therapeutic efficacy and disease course among patients, the hope for the future is to understand FL biology more deeply, to better comprehend how to obtain more representative samples and pre-treatment prognostic information in order to individualize the treatment strategy as early as frontline therapy. 

Cite This Article

Casadei B, Nanni L, Lolli G, Zinzani PL. Follicular lymphoma: the diminishing role of chemotherapy. J Cancer Metastasis Treat 2022;8:[Accept]. http://dx.doi.org/10.20517/2394-4722.2022.05

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties